News Conference News HFSA 2025 Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM Yael L. Maxwell October 01, 2025
News Conference News HFSA 2025 Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74 Yael L. Maxwell September 30, 2025
News Conference News HFSA 2025 CCM-D Delivers Safe, Effective Integrated Therapy in HFrEF Yael L. Maxwell September 29, 2025
News Conference News HFSA 2024 EXPANDed: Atrial Secondary MR Patients Get Clinical Benefit From TEER Caitlin E. Cox October 03, 2024
News Conference News HFSA 2024 FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone? Michael O'Riordan October 02, 2024
News Conference News HFSA 2023 ANTHEM-HFrEF Fails to Show Benefit of Vagal Nerve Stimulation Over GDMT Yael L. Maxwell October 16, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019